Anixa Biosciences
Anixa, a biotech firm, harnesses the immune system to combat cancer, develops cancer vaccines, and offers early tumor detection technology.
Founded
1982Anixa, a biotech firm, harnesses the immune system to combat cancer, develops cancer vaccines, and offers early tumor detection technology.
Anixa Biosciences, founded with a mission to harness the body's immune system to combat cancer, focuses on developing innovative therapies and vaccines for oncology. The company's core products include a cancer vaccine targeting α-Lactalbumin to prevent triple-negative breast cancer (TNBC) and a novel CAR-T based immunotherapy known as chimeric endocrine receptor T-cell (CER-T) technology. Anixa also offers Cchek™, a liquid biopsy technology for early tumor detection, addressing critical unmet needs in cancer treatment and prevention.
Notable figures affiliated with Anixa include its leadership team and key investors who have supported the company's pioneering work in biotechnology. Anixa has achieved significant milestones, such as advancing its CAR-T and cancer vaccine programs through various stages of development. The company's impact is marked by its potential to revolutionize cancer treatment and prevention, offering hope to patients through cutting-edge immunotherapy and early detection solutions.
Companies similar to Anixa Biosciences include Xenetic Biosciences, Chimera Bioengineering, Cancervax and Alaunos Therapeutics.
Anixa Biosciences was founded in 1982.
Anixa Biosciences' headquarters is located in San Jose, CA, US.
As of Dec 6, 2023, Anixa Biosciences has disclosed funding of $34.3M (USD). Undisclosed round amounts are excluded.
Anixa Biosciences has 4 employees as of Feb 6, 2024.
Alaunos Therapeutics
alaunos.com
